Intech Investment Management LLC reduced its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 27.6% during the third quarter, Holdings Channel.com reports. The fund owned 27,080 shares of the specialty pharmaceutical company’s stock after selling 10,304 shares during the period. Intech Investment Management LLC’s holdings in Jazz Pharmaceuticals were worth $6,270,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Thoroughbred Financial Services LLC increased its position in Jazz Pharmaceuticals by 5.8% during the 3rd quarter. Thoroughbred Financial Services LLC now owns 7,106 shares of the specialty pharmaceutical company’s stock valued at $1,645,000 after purchasing an additional 392 shares during the period. Hantz Financial Services Inc. raised its holdings in Jazz Pharmaceuticals by 17.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 4,659 shares of the specialty pharmaceutical company’s stock worth $1,079,000 after purchasing an additional 698 shares during the last quarter. Aberdeen Group plc lifted its position in shares of Jazz Pharmaceuticals by 16.5% in the 3rd quarter. Aberdeen Group plc now owns 97,422 shares of the specialty pharmaceutical company’s stock worth $22,555,000 after purchasing an additional 13,816 shares during the period. JW Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $2,547,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Jazz Pharmaceuticals by 50.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 76,421 shares of the specialty pharmaceutical company’s stock worth $17,696,000 after purchasing an additional 25,671 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling
In related news, CEO Renée Galá sold 1,000 shares of the business’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $225.37, for a total transaction of $225,370.00. Following the transaction, the chief executive officer owned 140,394 shares in the company, valued at $31,640,595.78. The trade was a 0.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,413 shares of the business’s stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total transaction of $326,911.68. Following the transaction, the chief accounting officer owned 6,512 shares in the company, valued at $1,506,616.32. The trade was a 17.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 171,342 shares of company stock worth $41,420,491 over the last ninety days. 4.10% of the stock is owned by company insiders.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. Piper Sandler upped their price objective on shares of Jazz Pharmaceuticals from $310.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, November 12th. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Barclays boosted their target price on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, November 3rd. Stifel Nicolaus set a $275.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group set a $300.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $294.25.
View Our Latest Stock Analysis on Jazz Pharmaceuticals
Jazz Pharmaceuticals Trading Up 0.4%
Shares of JAZZ stock opened at $240.71 on Wednesday. The company has a market cap of $15.45 billion, a P/E ratio of 81.87, a PEG ratio of 0.43 and a beta of 0.38. The stock has a 50 day simple moving average of $229.00 and a two-hundred day simple moving average of $220.37. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.64 and a current ratio of 1.82. Jazz Pharmaceuticals PLC has a fifty-two week low of $156.95 and a fifty-two week high of $266.38.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.03) by $0.15. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The company’s revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $8.13 earnings per share. Research analysts forecast that Jazz Pharmaceuticals PLC will post 11.18 earnings per share for the current year.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
